Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Interventions for treating intrahepatic cholestasis in people with sickle cell disease.

Martí-Carvajal, Arturo J; Simancas-Racines, Daniel.
Cochrane Database Syst Rev; (3): CD010985, 2015 Mar 13.
Artigo em Inglês | MEDLINE | ID: mdl-25769029

BACKGROUND:

Sickle cell disease is the most common hemoglobinopathy occurring worldwide and sickle cell intrahepatic cholestasis is a complication long recognized in this population. Cholestatic liver diseases are characterized by impaired formation or excretion (or both) of bile from the liver. There is a need to assess the clinical benefits and harms of the interventions used to treat intrahepatic cholestasis in people with sickle cell disease.

OBJECTIVES:

To assess the benefits and harms of the interventions for treating intrahepatic cholestasis in people with sickle cell disease. SEARCH

METHODS:

We searched the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched the LILACS database (1982 to 7 July 2014) and the WHO International Clinical Trials Registry Platform Search Portal (7 July 2014).Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register 10 October 2014. SELECTION CRITERIA We searched for published or unpublished randomised controlled trials. DATA COLLECTION AND

ANALYSIS:

Each author intended to independently extract data and assess the risk of bias of the trials by standard Cochrane Collaboration methodologies; however, no trials were included in the review. MAIN

RESULTS:

There were no randomised controlled trials identified. AUTHORS'

CONCLUSIONS:

This Cochrane Review did not identify any randomised controlled trials assessing interventions for treating intrahepatic cholestasis in people with sickle cell disease. Randomised controlled trials are needed to establish the optimum treatment for this condition.
Selo DaSilva